| Properties | Information |
|---|---|
| PhytoCAT-ID | PhytoCAT-1615 |
| Phytochemical name or plant extracts | Diosmin |
| PMID | 34582664 |
| Literature evidence | The combination of PGV-1 and diosmin performs a potential as a combinatorial anticancer drug for TNBC. |
| IUPAC name | 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one |
| Phytochemicals’ class or type of plant extracts | Flavonoid |
| Source of phytochemicals or plant Extracts | NA |
| Geographical availability | NA |
| Plant parts | NA |
| Other cancers | Breast cancer |
| Target gene or protein | AURKA, CDK1, KIF11. |
| Gene or Protein evidence | The synergistic effect of the co-treatment is likely to target AURKA, CDK1, and KIF11. |
| Target pathways | NA |
| IC50 | NA |
| Potency | Taken together, diosmin that acts at low micromolar range against breast cancer cells may be considered as a promising candidate for anticancer therapy. |
| Cell line/ mice model | MCF-7, MDA-MB-231, SKBR-3 |
| Additional information | In addition, diosmin, synthesized diosmin derivatives, and some identified terpenes were found to have anti-diabetic activities. |
| PubChem ID | 5281613 |
| Additional PMIDs | 27890807 |
| Additional sources of information | NA |
| Safety | NA |